DBD vs ASAN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

DBD

53.4
AI Score
VS
DBD Wins

ASAN

35.1
AI Score

Investment Advisor Scores

DBD

53score
Recommendation
HOLD

ASAN

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DBD ASAN Winner
Revenue 2.82B 421.52M DBD
Net Income 27.10M -53.59M DBD
Gross Margin 24.8% 86.8% ASAN
Net Margin 1.0% -12.7% DBD
Operating Income 128.80M -56.46M DBD
ROE 2.9% -51.4% DBD
ROA 0.7% -6.6% DBD
Total Assets 3.66B 816.15M DBD
Current Ratio 1.27 0.92 DBD

Relative Price Performance (Last 90 Days)

DBD 1M: -9.4% · 3M: -20.1% ASAN 1M: -3.0% · 3M: +6.7%

Current Technical Phase

DBD

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 38

RSI (14): 38.3 · Price: $57.34

ASAN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 39

RSI (14): 39.3 · Price: $9.59

Fundamentals Snapshot

Metric DBD ASAN
Market Cap — —
Forward P/E 9.3 27.0
Trailing P/E 28.5 —
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.3% 0.9%
Operating Margin 0.1% -0.2%
EPS 2.11 -0.66
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DBD is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.